Cardiac hormones target nuclear oncogenes c‐<scp>F</scp>os and c‐<scp>J</scp>un in carcinoma cells

Manimala, Neil J.; Frost, Chelsea; Lane, Meghan L.; Higuera, Mariana; Beg, Rana; Vesely, David L.

doi:10.1111/eci.12153

Cited by 19 publications

(15 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the p-c-Jun protein level increased in the U0126 group. These observations suggested that ERK1/2 might promote the proliferation of Hela and C33A cells through increasing the activation of p-c-Fos protein, while the result of c-Jun protein level increasing after p-ERK1/2 inhibited is opposite to the expectation [17], and the cause should be focused on the further study.…”

Section: Discussionmentioning

confidence: 92%

See 1 more Smart Citation

ERK1/2 promoted proliferation and inhibited apoptosis of human cervical cancer cells and regulated the expression of c-Fos and c-Jun proteins

et al. 2015

View full text Add to dashboard Cite

Small-molecule inhibitors targeted MAPK have been wildly used for some cancer therapeutics as a biologically viable model, but no one has been used for cervical caner. ERK1/2, one of MAPK kinases, is expressed high in cervical cancer tissue. The aim of the present study was to evaluate the effects of ERK1/2 inhibitor U0126 on proliferation and apoptosis of cervical cancer cells and appraise the correlated mechanism of the effects. In this study, the cell proliferation of Hela and C33A cervical cancer cells was tested by Cell Counting Kit-8 (CCK8) assay and cell counting after treated with ERK1/2 inhibitor U0126. The cell cycle and apoptosis were evaluated by flow cytometry (FCM). The protein levels of ERK1/2 and c-Fos and c-Jun were detected by Western blot. The results indicated that after down-regulating ERK1/2 proteins with the inhibitor U0126, Hela and C33A cells proliferation was inhibited, cell apoptosis was promoted, the proportions of G0/G1 stage in cell cycle increased, and G2/M stages decreased. After down-regulating ERK1/2 proteins of Hela and C33A cells, the expression levels of p-c-Fos protein decreased, while p-c-Jun protein increased. The results of this study indicated that ERK1/2 may promote the development of cervical cancer cells, suggesting ERK1/2 inhibitor may be used as an effective target for cervical cancer therapies working for. It might inhibit cervical cancer cells growth via regulating the transcription factors expression of c-Fos and c-Jun.

show abstract

Section: Discussionmentioning

confidence: 92%

“…Among these proteins, c-Fos and c-Jun are the major subunits of AP-1 which involved in cell proliferation and cell cycle [16] and decreased in carcinoma cells after treated with ERK1/2 inhibitor [17].…”

Section: Introductionmentioning

confidence: 99%

ERK1/2 promoted proliferation and inhibited apoptosis of human cervical cancer cells and regulated the expression of c-Fos and c-Jun proteins

et al. 2015

View full text Add to dashboard Cite

show abstract

“…It also coordinates with other genes (particularly ERK/MAPK pathway components) to promote cancer cell invasion and migration (Wolfer and Ramaswamy, 2011). And for proto-oncogene c-Fos, it dimerizes with c-Jun to form AP-1 protein to induce transcription of various genes concerning proliferation, differentiation and transformation of cancer (Manimala et al, 2013). All of the three genes play vital roles in carcinogenesis and progression.…”

Section: Discussionmentioning

confidence: 99%

Hydroxysafflor yellow A inhibits angiogenesis of hepatocellular carcinoma via blocking ERK/MAPK and NF-κB signaling pathway in H22 tumor-bearing mice

Yang

Zhu³

et al. 2015

European Journal of Pharmacology

View full text Add to dashboard Cite

“…However, the specific cause of the elevation of natriuretic peptide plasma levels seen in cancer has not been elucidated. In recent years, it has been demonstrated that natriuretic peptides, or compounds with similar activity, decrease the number of several cancer cells in vitro through a reduction of DNA synthesis [ 32 ] and inhibition of c-Fos and c-Jun protooncogenes [ 33 ], inhibit lung metastases and skin carcinogenesis in animal models [ 34 , 35 ], and diminish the expression of vascular endothelial growth factor and that of its receptor VEGFR2, thus having the potential to control vasculogenesis [ 36 ]. One work has shown opposite effects of natriuretic peptides on carcinogenesis depending on their concentrations [ 37 ].…”

Section: Discussionmentioning

confidence: 99%

N-Terminal Pro-Brain Natriuretic Peptide Is Associated with a Future Diagnosis of Cancer in Patients with Coronary Artery Disease

et al. 2015

View full text Add to dashboard Cite

ObjectiveSeveral papers have reported elevated plasma levels of natriuretic peptides in patients with a previous diagnosis of cancer. We have explored whether N-terminal pro-brain natriuretic peptide (NT-proBNP) plasma levels predict a future diagnosis of cancer in patients with coronary artery disease (CAD).MethodsWe studied 699 patients with CAD free of cancer. At baseline, NT-proBNP, galectin-3, monocyte chemoattractant protein-1, soluble tumor necrosis factor-like weak inducer of apoptosis, high-sensitivity C-reactive protein, and high-sensitivity cardiac troponin I plasma levels were assessed. The primary outcome was new cancer diagnosis. The secondary outcome was cancer diagnosis, heart failure requiring hospitalization, or death.ResultsAfter 2.15±0.98 years of follow-up, 24 patients developed cancer. They were older (68.5 [61.5, 75.8] vs 60.0 [52.0, 72.0] years; p=0.011), had higher NT-proBNP (302.0 [134.8, 919.8] vs 165.5 [87.4, 407.5] pg/ml; p=0.040) and high-sensitivity C-reactive protein (3.27 [1.33, 5.94] vs 1.92 [0.83, 4.00] mg/L; p=0.030), and lower triglyceride (92.5 [70.5, 132.8] vs 112.0 [82.0, 157.0] mg/dl; p=0.044) plasma levels than those without cancer. NT-proBNP (Hazard Ratio [HR]=1.030; 95% Confidence Interval [CI]=1.008-1.053; p=0.007) and triglyceride levels (HR=0.987; 95%CI=0.975-0.998; p=0.024) were independent predictors of a new cancer diagnosis (multivariate Cox regression analysis). When patients in whom the suspicion of cancer appeared in the first one-hundred days after blood extraction were excluded, NT-proBNP was the only predictor of cancer (HR=1.061; 95%CI=1.034-1.088; p<0.001). NT-proBNP was an independent predictor of cancer, heart failure, or death (HR=1.038; 95%CI=1.023-1.052; p<0.001) along with age, and use of insulin and acenocumarol.ConclusionsNT-proBNP is an independent predictor of malignancies in patients with CAD. New studies in large populations are needed to confirm these findings.

show abstract

Cardiac hormones target nuclear oncogenes c‐Fos and c‐Jun in carcinoma cells

Abstract: Four cardiac hormones are potent inhibitors of c-Fos and c-Jun proto-oncogenes within the nucleus of cancer cells.

Cited by 19 publications

References 23 publications

ERK1/2 promoted proliferation and inhibited apoptosis of human cervical cancer cells and regulated the expression of c-Fos and c-Jun proteins

ERK1/2 promoted proliferation and inhibited apoptosis of human cervical cancer cells and regulated the expression of c-Fos and c-Jun proteins

Hydroxysafflor yellow A inhibits angiogenesis of hepatocellular carcinoma via blocking ERK/MAPK and NF-κB signaling pathway in H22 tumor-bearing mice

N-Terminal Pro-Brain Natriuretic Peptide Is Associated with a Future Diagnosis of Cancer in Patients with Coronary Artery Disease

Contact Info

Product

Resources

About